biopharma-reporter5m
Amgen announces positive Phase 2 results for its GLP-1-GIP weight loss drug
MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
biopharma-reporter1d
Biohaven’s myostatin inhibitor fails in phase 3 spinal muscular atrophy trial
Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.
biopharma-reporter1d
BridgeBio wins FDA approval for inherited cardiomyopathy treatment
California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...
biopharma-reporter2d
We’ve upgraded BioPharmaReporter to give you more of what you love
We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...
biopharma-reporter7d
Phase 3 win for Protagonist Therapeutics with oral plaque psoriasis drug
The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...
biopharma-reporter7d
Samsung Biologics and European pharma company enter major manufacturing deal
The global contract development and manufacturing organization ​ (CDMO), Samsung Biologics, announced this week that it has ...
biopharma-reporter7d
Samsung Biologics and European pharma company enter major manufacturing deal
The global contract development and manufacturing organization (CDMO), Samsung Biologics, announced this week that it has entered into a collaboration with an undisclosed European pharmaceutical ...
biopharma-reporter8d
Helen Harrington’s journey: Patience, passion, and problem-solving
From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of ...